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Abstract: 
Few studies have examined the extent to which structural and 
functional MRI, alone and in combination with genetic biomarkers, can predict 
future cognitive decline in asymptomatic elders. This prospective study 
evaluated individual and combined contributions of demographic information, 
genetic risk, hippocampal volume, and fMRI activation for predicting cognitive 
decline after an 18-month retest interval. Standardized neuropsychological 
testing, an fMRI scans semantic memory task (famous name discrimination), 
and structural MRI (sMRI) were performed on 78 healthy elders (73% female; 
mean age = 73 years, range = 65 to 88 years). Positive family history of 
dementia and presence of one or both apolipoprotein E (APOE) ε4 alleles 
occurred in 51.3% and 33.3% of the sample, respectively. Hippocampal 
volumes were traced from sMRI scans. At follow-up, all participants 
underwent a repeat neuropsychological examination. At 18 months, 27 
participants (34.6%) declined by at least 1 SD on one of three 
neuropsychological measures. Using logistic regression, demographic 
variables (age, years of education, gender) and family history of dementia did 
not predict future cognitive decline. Greater fMRI activity, absence of an APOE 
ε4 allele, and larger hippocampal volume were associated with reduced 
likelihood of cognitive decline. The most effective combination of predictors 
involved fMRI brain activity and APOE ε4 status. Brain activity measured from 
task- activated fMRI, in combination with APOE ε4 status, was successful in 
identifying cognitively intact individuals at greatest risk for developing 
cognitive decline over a relatively brief time period. These results have 
implications for enriching prevention clinical trials designed to slow AD 
progression. 
Keywords: aging, apolipoprotein E, cognitive decline, fMRI, hippocampal 
volume, neuroimaging, memory. 
INTRODUCTION 
Alzheimer’s disease (AD) neuropathology begins decades before 
the onset of observable symptoms [1]. Initiating interventions after 
symptom onset may be too late to make a meaningful impact on 
disease course. Clinical trials designed to prevent or slow AD 
progression have dramatically intensified the search for valid 
preclinical biomarkers. Extant biomarker studies  have demonstrated 
success in predicting conversion from mild cognitive impairment (MCI) 
to  AD using neuropsychological testing [2-5]; structural magnetic 
resonance imaging (sMRI) measurement of hippocampal volume [6-8] 
and rate of atrophy [9-11]; sMRI of entorhinal cortex volume [11-14]; 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Alzheimer’s Disease, Vol. 21, No. 3 (September 2010): pg. 871-885. DOI. This article is © IOS Press and 
permission has been granted for this version to appear in e-Publications@Marquette. IOS Press does not grant 
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from IOS 
Press. 
4 
 
cerebrospinal fluid (CSF) indices including elevated isoprostane [15-
17], elevated total tau and phosphorylated tau [18-20], and low 
amyloid-β (Aβ)42 levels [15, 21-23]; positron emission tomography 
(PET) involving regional glucose metabolism [24, 25]  and amyloid 
imaging using the 11C Pittsburgh Compound B [26-28]; and task-
activated functional magnetic resonance imaging (fMRI); [29, 30]. A 
more challenging task for prevention trials, however, is to identify 
biomarkers capable of identifying asymptomatic older persons at-risk 
for developing cognitive decline within the time frame required of a 
prevention trial (2-3 years).  
The apolipoprotein E (APOE) ε4 allele is a well-known risk factor 
for late onset AD [31, 32], and healthy APOE ε4 carriers have 
demonstrated faster cognitive decline than non-carriers [33-35]. 
However, the biomarker potential for APOE alone is limited, given that 
the APOE ε4 allele frequency is less than 40% among AD cases [36, 
37], and it has a low positive predictive value   for AD diagnosis [38-
40]. Using test-retest intervals of approximately three years, studies 
using fluorodeoxyglucose (FDG) PET [34] and CSF tau181/Aβ42 and 
ptau181/Aβ42 ratios [41] have shown promise for predicting cognitive 
decline in otherwise healthy older adults. The relative invasiveness of 
these latter two approaches may preclude their routine use in 
screening large numbers of cognitively intact participants for inclusion 
in prevention trials. 
Less invasive magnetic resonance imaging (MRI) techniques 
provide more practical alternatives for identifying cognitively intact 
older adults at risk for future cognitive decline. sMRI studies have 
demonstrated that smaller hippocampal and entorhinal cortex volumes 
at baseline predict cognitive decline in healthy elders [42-47]. A task-
activated fMRI study [48] has also shown that increased number and 
spatial extent of activated regions at baseline can predict memory 
decline after a two-year retest interval. Genetic risk in middle aged 
women (family history of AD and at least one APOE ε4 allele) has been 
associated with decreased fMRI activation in extrastriate and posterior 
inferotemporal cortex at baseline, together with further decreases 
after four years in these regions as well as left inferior frontal and 
premotor cortex [49]. However, this decreased fMRI signal was not 
associated with cognitive decline in this   study. In contrast, using a 
word categorization task during fMRI with APOE ε4 carriers, nine older 
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adults showing cognitive stability on episodic memory testing after five 
years demonstrated increased left inferior parietal activation at 
baseline relative to nine participants who demonstrated episodic 
memory decline; greater blood oxygen level dependent (BOLD) fMRI 
response in this region was associated with better memory 
performance after five years [50]. However, no hippocampal volume 
differences were observed at baseline between stable and declining 
participants. No study to date has directly compared the relative 
sensitivity of sMRI and fMRI approaches, particularly over a relatively 
brief interval (e.g., 1-2 years). 
In this study, we compared the ability of sMRI and fMRI to 
predict cognitive decline over 18 months in a sample of cognitively 
intact older adults with varying degrees of AD risk, based on family 
history of dementia and APOE ε4 allele carrier status. The sMRI 
technique involved measurement of hippocampal volumes. The fMRI 
task required the discrimination of famous from unfamiliar names. Our 
previous studies using this task reported activation of a semantic 
memory system, including bilateral hippocampi, posterior cingulate, 
middle frontal gyrus, and lateral temporoparietal junction [51-53]. The 
task can be performed with a high degree of accuracy (>90% correct) 
even in symptomatic amnestic MCI patients [54]. In a cross-sectional 
study [55], we demonstrated that the brain activation patterns of 
healthy elders at risk for developing AD (APOE ε4, family history) 
could be differentiated using this task. The current longitudinal 
prospective study used logistic regression to compare the relative 
efficacy of sMRI and fMRI, alone and in combination, for predicting 
cognitive decline after an 18-month retest interval. Because a greater 
potential exists for accelerated cognitive decline among APOE ε4 
carriers [33-35], we examined APOE genotype as an additional 
predictor of decline. 
MATERIALS AND METHODS 
Participants 
Participants were 78 healthy older adults (73% female; Mage=73 
years, SD= 4.9 years; Meducation=14.9 years, SD = 2.7 years). The 
participants were drawn from a larger sample of 459 community-
dwelling adults who were recruited via newspaper advertisements. 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Alzheimer’s Disease, Vol. 21, No. 3 (September 2010): pg. 871-885. DOI. This article is © IOS Press and 
permission has been granted for this version to appear in e-Publications@Marquette. IOS Press does not grant 
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from IOS 
Press. 
6 
 
Following telephone screening, 92 participants met study inclusion and 
exclusion criteria, and 81 persons agreed to undergo ApoE genotyping 
from blood samples, a neuropsychological evaluation, and an fMRI 
scanning session. MRI data were not able to be obtained for three 
participants. Family history was defined as a report of a clear clinical 
diagnosis of AD or a reported history of gradual decline in memory and 
other cognitive functions, confusion, or judgment problems without a 
formal diagnosis of AD prior to death in a first-degree relative. One 
participant reported a diagnosis of AD in a second degree relative, with 
some mild cognitive changes noted in a parent prior to the parent’s 
death. Because our study examined the influence of AD risk factors on 
prediction of cognitive decline, half of the participants were purposely 
selected because they had a positive family history of AD. We 
expected that enrichment of our sample with persons with a positive 
family history of AD would also increase the number of persons who 
were APOE ε4 positive, because APOE ε4 tends to be more common 
among individuals with a positive AD family history than among those 
with a negative AD family history [56, 57]. 
Family history of dementia was present in 51.3% of 
participants, and 33.3% of the sample carried the APOE ε4 allele. All 
participants underwent neuropsychological evaluation (see below) and 
were cognitively intact when entering the study. Informed consent was 
obtained consistent with the Declaration of Helsinki and institutional 
guidelines established by the Medical College of Wisconsin Human 
Subjects Review Committee; all participants received financial 
compensation. 
Neuropsychological assessment and APOE genotyping 
All participants underwent baseline neuropsychological testing, 
fMRI scanning, and APOE genotyping. The neuropsychological battery 
included the Mini-Mental State Examination [58], Mattis Dementia 
Rating Scale-2 (DRS-2) [59, 60], Rey Auditory Verbal Learning Test 
(RAVLT) [61], Geriatric Depression Scale [62], and Lawton 
Instrumental Activities of Daily Living Scale (ADL) [63]. Alternate 
forms of the DRS-2 [64, 65] and RAVLT [66] were used. APOE 
genotype was determined using a PCR method [67]. DNA was isolated 
with Gentra Systems Autopure LS for Large Sample Nucleic Acid 
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Purification. All participants underwent a follow-up neuropsychological 
examination after approximately 18 months. 
Definition of cognitive decline 
We defined cognitive decline as a reduction from baseline 
performance of at least one SD on at least one of the three principal 
outcome indices (DRS-2, RAVLT Sum of Trials 1-5 [T1-5], RAVLT 
Delayed Recall [DR]). Residualized change scores were computed for 
each cognitive measure by predicting T2 scores using T1 scores; this 
procedure adjusts for baseline performance, practice effects, and 
regression to the mean [68-70]. Participants with standardized 
residuals of -1.0 or lower were assigned to the cognitively declining 
group; the remaining participants were classified as cognitively stable. 
fMRI task 
For the fame discrimination task [53], stimuli consisted of 30 
famous and 30 unfamiliar names randomly interspersed with 20 
presentations of a centrally placed crosshair in order to introduce 
“jitter” into the fMRI time series (interstimulus interval = 4 sec). 
Participants made a right index or right middle finger key press for 
famous or unfamiliar names, respectively. Accuracy and reaction time 
were recorded, and nonparametric signal detection indices were 
calculated [71]. The imaging run began and ended with 12 sec of 
fixation and was 5 min and 44 sec in duration. 
Image acquisition 
Whole-brain, event-related fMRI was conducted on a General 
Electric (Waukesha, WI)  Signa Excite 3.0 Tesla short bore scanner 
equipped with a quad split quadrature transmit/receive head coil. 
Echoplanar images were collected using an echoplanar pulse sequence 
(TE=25 ms; flip angle=77 degrees; field of view (FOV)=24 cm; matrix 
size=64 x 64; TR=2s). Thirty-six contiguous axial 4-mm-thick slices 
provided coverage of the entire brain (voxel size = 3.75 x 3.75 x 4 
mm). High-resolution, three-dimensional spoiled gradient-recalled at 
steady-state (SPGR) anatomic images were acquired (TE = 3.9 ms; TR 
= 9.5 ms; inversion recovery (IR) preparation time = 450 ms; flip 
angle = 12 degrees; number of excitations (NEX) = 2; slice thickness 
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= 1.0 mm; FOV = 24 cm; resolution = 256 x 224). Foam padding was 
used to reduce head movement within the coil. 
Image analysis 
Functional images were generated with the Analysis of 
Functional NeuroImages (AFNI) software package [72]. Each image 
series was time shifted to the beginning of the TR and spatially 
registered to reduce head motion effects using a rigid body iterative 
linear least squares method. A deconvolution analysis was used to 
extract separate hemodynamic response functions (HRFs) for correctly 
recognized famous and unfamiliar names. HRFs were modeled for the 
0-16 second period post-stimulus onset. Motion parameters and 
incorrect trials were incorporated into the model as nuisance 
regressors. Area under the curve (AUC) was calculated by summing 
the hemodynamic responses at time points 4, 6, and 8 seconds post 
trial onset, a measure of the   curve peak yielding maximum signal-to-
noise. Anatomical and functional scans were transformed into standard 
stereotaxic space [73]. To compensate for anatomical variation, 
functional images were blurred using a 6 mm Gaussian full-width half-
maximum filter. 
Spatial extent of activation for cognitively stable and 
declining groups 
Voxelwise t-tests were used to generate separate statistical 
parametric maps for the stable and declining groups. These maps 
indicate regions where the AUCs for famous and unfamiliar names 
were significantly different. The statistical threshold was based on an 
individual voxel probability (p = 0.005) coupled with a minimum 
cluster volume (0.73 ml). These values were derived from 3,000 
Monte Carlo simulations [74] and correspond to a whole brain family-
wise error threshold of p < 0.05. 
Functional ROI analysis 
A separate voxelwise t-test, comparing famous and unfamiliar 
names, was conducted on all 78 participants using the identical 
statistical threshold. This method identified significant cluster volumes, 
which we refer to as functional regions of interest (fROIs). For each 
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participant, an “average AUC” was calculated for all voxels within each 
fROI. These data were then subjected to a principal components 
analysis (PCA) to further reduce the number of regions that would 
serve as predictors in the logistic regression analysis (see below). 
Hippocampal volume measurement 
Left and right hippocampal volumes were created using 
Freesurfer [75, 76] and manually edited on T1-weighted SPGR images 
by two raters blinded to participant group membership. Using coronal 
views, the mask was further refined by excluding the fimbria and 
alveus and retaining the hippocampus (uncal apex, cornu ammonis, 
subiculum, gyrus of retzius, and fasciola cinerea). Hippocampal 
volumes were normalized by dividing by the total intracranial volume. 
Intraclass correlation for the two raters was 0.87. The left and right 
hippocampal volumes were then summed to create a single score. 
Data analysis 
Statistical analyses were performed using R, version 2.9.0. 
Group differences on demographics, total hippocampal volume, and 
neuropsychological and fMRI task performance were compared using t-
tests and r2 effect size measures or Fisher’s Exact tests, as 
appropriate. Logistic regression tested the ability of specific baseline 
variables to discriminate between stable and declining participants. To 
avoid overfitting the data and to maintain a reasonable subjects-to- 
variables ratio for each model, we restricted the set of predictors to no 
more than four variables. Our models tested the effects of age, 
education, and gender (Model 1); APOE ε4 status and dementia family 
history (Model 2); hippocampal volume (Model 3); fMRI activation 
(Model 4). Models 5 and 6 examined the additive effect of APOE ε4 
status with either hippocampal volume or fMRI activation, respectively. 
Model 7 combined APOE ε4 status with both imaging predictors. The 
ability of these models to differentiate between stable and declining 
participants was assessed using the Nagelkerke R2 and the 
concordance or C index (related to the area under the receiver 
operating characteristic curve [77]. The Nagelkerke R2 assesses the 
importance of the predictors in a given model relative to a “perfectly 
fitting” null model [78]. The C index reflects the proportion of all 
possible pairs of declining and stable subjects in which the declining 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Journal of Alzheimer’s Disease, Vol. 21, No. 3 (September 2010): pg. 871-885. DOI. This article is © IOS Press and 
permission has been granted for this version to appear in e-Publications@Marquette. IOS Press does not grant 
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from IOS 
Press. 
10 
 
participant in the pair had a higher predicted probability of decline 
than the stable participant   [77]. Values of R2 and C for each logistic 
regression model were validated with a bootstrapping analysis using 
5000 resamples in order to assess each model’s accuracy of prediction 
of decline across the entire range of probabilities [77]. This approach 
yielded bootstrap-corrected values for R2 and C. Bootstrapping is the 
most efficient model validation procedure, as it does not require 
holding out any data for cross-validation, and each phase of model 
development (including assessment of the degree of overfitting the 
data) is revalidated using repeated resampling from the entire sample 
[77]. 
RESULTS 
Identification of cognitive decline 
A total of 27/78 (34.6%) participants showed a one SD decline 
on at least one of the three neuropsychological indices (DRS-2, RAVLT 
Trials 1-5, and RAVLT Delayed Recall). These participants constituted 
the cognitively declining group and the remaining participants formed 
the stable group. Figure 1 illustrates performance changes on the 
neuropsychological outcome measures for the stable and declining 
groups. As expected, the stable group showed no significant 
neuropsychological change after 18 months, while the declining group 
demonstrated significant reductions on each of the three 
neuropsychological indices. 
Subjective memory complaints were present in 33.3% of the 
declining group. Of the declining participants, 2 (7.6%) satisfied 
criteria for MCI [79]. No participant demonstrated impaired ADL skills 
at follow-up. Declining participants did not differ from stable 
participants on age, education, gender, or neuropsychological retest 
interval (Table 1). However, the APOE ε4 allele was over twice as 
prevalent (51.9% versus 23.6%) among declining (3 ε2/ε3, 10 ε3/ε3, 
14 ε3/ε4) than stable (5 ε2/ε3, 34 ε3/ε3, 11 ε3/ε4, 1 ε4/ε4) 
participants. 
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Baseline neuropsychological testing and fMRI task 
performance 
On baseline measures (Table 1), no significant differences were 
observed on the MMSE, DRS-2, RAVLT Trials 1-5, and RAVLT Delayed 
Recall between the stable and declining groups after controlling for 
multiple comparisons (Bonferroni adjusted alpha level = 0.0125; 
0.05/4  tests). The stable group reported significantly more depressive 
symptoms on the GDS, but no participant in either group was in the 
clinically depressed range. None of the participants   reported ADL 
impairments at baseline. 
On the fMRI fame discrimination task, no differences were 
observed in accuracy, RT, or on a signal detection measure of 
discriminability (d’) between the stable and declining groups. For   
both groups, mean accuracy exceeded 90% for identification of 
famous names and rejection of unfamiliar names. 
Baseline sMRI 
Declining participants had a significantly smaller total 
hippocampal volume at baseline than cognitively stable participants 
(Table 1). 
Baseline fMRI 
Figure 2 presents significant clusters based on a voxelwise 
analysis performed separately for the stable and declining groups. The 
spatial extent of activated voxels is greater in the stable than declining 
group, with most of the differences reflecting more activation during 
recognition of famous names relative to unfamiliar names. The 
declining group showed a smaller amount of activated tissue, with 
some regions showing the opposite pattern. 
Figure 3A represents the results of the voxelwise analysis 
performed on the entire sample. This analysis, restricted to the famous 
> unfamiliar name comparison, yielded eight fROIs (Table 2). A PCA 
was conducted on the average AUCs of these fROIs, yielding two 
components accounting for 73% of total variance (Table 2). Five fROIs 
loaded significantly on a “Cortical” component, shown in green in 
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Figure 3A, whereas two regions loaded on the “Hippocampal” 
component (purple regions in Figure 3A). The right cerebellum did not 
demonstrate significant loadings [80] on either component and was 
dropped from the analysis. The unfamiliar > famous name comparison 
resulted in four fROIs and a single PCA component accounting for 
63.3% of the total variance. This component did not predict cognitive 
decline and is not discussed   further. 
Figure 3B presents a graph of the fMRI signal response to 
famous and unfamiliar names compared to fixation (rather than just 
the comparison of these conditions) to address the question of 
whether the effect is driven primarily by activation to famous names or 
the response to novel names. For cognitively stable participants, both 
the Cortical and Hippocampal fMRI signal demonstrated positive 
changes in the AUC in response to famous names and a decreased 
AUC in response to unfamiliar names. In contrast, the cognitively 
declining participants showed the opposite pattern, with greater AUC 
in response to unfamiliar names and reduced AUC when presented 
with unfamiliar names. Using a mixed-design ANOVA that tested the 
effects of group (stable vs. declining) and stimulus type (famous vs. 
unfamiliar), significant group by stimulus type interactions were 
observed for the Cortical (F(1,76)=8.88, p<0.004) and Hippocampal 
(F(1,76)=8.11, p=0.006) fMRI components. 
Logistic regression analyses 
Seven logistic regression models were evaluated. For each 
model, bootstrap-corrected R2 and C values are presented in Table 3. 
For each predictor within a model, coefficients, standard errors, and 
significance levels are shown in Table 3, and odds ratios with 95% 
confidence intervals are presented in Figure 4. Models 1 and 2 indicate 
that age, education, gender and family history of AD were not 
significant predictors of future cognitive decline. For Models 2-7, APOE 
status, cortical and hippocampal fMRI activation, and hippocampal 
volume each contributed significantly to the prediction of cognitive 
decline. Although Model 7 demonstrates the largest R2 (0.293) and C 
index (0.789), only two of the four predictors were statistically 
significant (cortical fMRI activation and APOE status), whereas the 
remaining two predictors (hippocampal fMRI and hippocampal volume) 
were not. Model 5 (R2 = 0.285; C = 0.787) was   the second best 
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model, with APOE genotype and both cortical and hippocampal fMRI   
activation each contributing significantly to the prediction of future 
cognitive decline. 
The Adequacy Index [77] is a recommended way of comparing 
the adequacy of a set of predictors across models. It is unitless and is 
represented by ratio of the -2 log likelihood statistic for testing a 
subset of predictors for the model of interest to the -2 log likelihood 
ratio statistic for testing the joint significance of the full set of 
predictors. It ranges between 0 (no predictive information for the 
subset of predictors) to 1 (complete predictive information for the 
subset of predictors). Using the full set of predictors in Model 7, the 
Adequacy Indexes for Models 2-6 are presented in Table 3. Model 1 
was not included as there was no significant predictor of decline using 
demographic variables. The fMRI measures alone (Model 3) account 
for 46% of the total explanatory power for the set of variables, 
compared to hippocampal volume alone (Model 4), which accounts for 
only 27% of the total explanatory power. Perhaps more dramatically,   
Model 5, which uses the fMRI measures plus APOE genotype status 
accounts for 87% of the explanatory power compared to Model 6 
(hippocampal volume plus APOE genotype status), which accounts for 
only 43% of the explanatory  power. 
DISCUSSION 
Clinical trials involving pharmacological and lifestyle (exercise, 
cognitive enrichment, diet) interventions are being considered to 
prevent or delay the onset of AD, even before symptoms emerge. For 
clinical trials to be maximally successful, enrichment of the sample 
with elders at the greatest risk for experiencing cognitive decline over 
the course of a typical clinical trial (2-3 years) is essential. Results of 
our prospective study indicate that combining genetic risk and MRI 
biomarkers can effectively identify such individuals, even after a 
relatively brief 18-month retest interval. Specifically, we were able to 
correctly order 78.9% of possible pairs of stable and declining 
participants using a combination of APOE genotype, cortical and 
hippocampal fMRI, and hippocampal volumes. APOE genotype and 
fMRI (cortical and hippocampal) predictors alone correctly ordered 
78.7% of possible pairs. In contrast, hippocampal volume, alone or 
combined with APOE status, correctly ordered only 68.7% and 70.2% 
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of pairs, respectively. Without the benefit of imaging data, family 
history of dementia and APOE status correctly ordered only 61.5% of 
possible pairs (chance prediction = 50%). Overall, our findings suggest 
that the combination of fMRI and APOE genotype status holds promise 
for successfully screening at-risk, but asymptomatic, participants for 
prevention trials. 
Our results would appear to be at odds with a similar 
prospective fMRI study [48], in which increased brain activation was 
associated with lower scores on episodic memory tasks after a two 
year retest interval. It is important to note two important 
methodological differences between the two studies. First, the number 
of participants who underwent follow-up neuropsychological testing in 
the earlier study (n = 14) was considerably smaller than those in the 
current study (n = 78). Second, the previous study used an effortful 
episodic learning and recall task and did not report task performance 
during fMRI scanning. It is conceivable that declining participants 
performed more poorly at baseline on the fMRI task than those who 
were stable over the retest interval. Such differences in task 
performance, if present, could have a meaningful impact on the 
pattern of brain activation, especially since error trials could not be 
eliminated from the blocked design trial format used in the previous 
fMRI study. In contrast, the current event-related study used a low 
effort, high accuracy (>90% correct) semantic memory task in which 
the few error trials that did occur were excluded from the final image 
analyses. 
In a previous study [55], we reported greater semantic memory 
activation in cognitively intact, APOE ε4 carriers relative to non-
carriers. As in the current study, we defined semantic memory 
activation by a greater BOLD response to famous than unfamiliar name 
stimuli. Based solely on the cross-sectional results reported in our 
previous study, one might predict that greater semantic activation 
would be a predictor of future cognitive decline. However, in our prior 
study, we did not segregate declining from stable participants within 
each of the two risk groups. The current longitudinal results suggest 
that having increased semantic memory activation may paradoxically 
afford a protective effect against future cognitive decline in both high 
and low risk individuals. This effect is illustrated in Figure 5. The 12 
APOE ε4 carriers in the stable group demonstrated greater cortical 
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activation in response to familiar than unfamiliar names; in   contrast, 
the 14 declining APOE ε4 carriers exhibited greater activation to 
unfamiliar than to familiar names. Among the non-carriers, a similar 
pattern was observed, albeit with less overall semantic memory 
activation for the group as a whole. Among the 39 stable non-carriers, 
the degree of cortical activation was comparable for famous and 
unfamiliar names, whereas the 13 declining non-carriers demonstrated 
greater activation for unfamiliar than famous   names. 
Our finding that increased baseline fMRI activation is protective 
against future cognitive decline in cognitively intact elders is consistent 
with prior studies reporting increased task- related BOLD signal in 
parietal cortex in cognitively stable participants after five years [50, 
81]. Increased activation may reflect greater cognitive reserve in 
asymptomatic persons, particularly   in regions subserved by the 
cholinergic system. Increased brain activation in these regions has 
been observed following administration of cholinesterase inhibitors in 
MCI and AD patients [82- 87]. We speculate that improved cognitive 
reserve, possibly manifested by increased neuronal firing rate or 
recruitment of additional supportive neuronal regions, permits 
continued   functioning at a higher level in the face of early 
neurodegenerative changes. Persons who have lost this propensity for 
functional compensation are at increased risk of future cognitive 
deterioration. 
Our famous name recognition task activates brain regions 
(posterior cingulate gyrus,   posterior inferior parietal cortex, middle 
temporal gyrus, fusiform and parahippocampal gyri, hippocampus, and 
medial superior frontal gyrus) commonly associated with the “default 
mode network” (DMN) [88, 89]. The DMN is frequently correlated with 
uncontrolled semantic processing resulting from task-unrelated 
thoughts that occur during resting scan conditions. Prior work by 
Binder and colleagues [90, 91] has demonstrated considerable overlap 
between brain systems associated with the resting state DMN and 
those activated by controlled semantic memory processing tasks. 
Recent studies [92-94] have suggested that disruption of the DMN can 
occur in early AD. Not surprisingly, our results have shown that 
participants who have experienced cognitive decline after 18 months 
also demonstrate reduced baseline semantic memory activation in 
cortical regions that overlap with the DMN (see Figure 5). Moreover, 
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the AUCs corresponding to the fMRI signal in both cortical and 
hippocampal regions were reduced in response to famous names and 
increased in response to unfamiliar names for cognitively declining 
participants (Figure 3B). Cognitively stable participants showed the 
opposite pattern. Future studies are required to determine the relative 
sensitivity of baseline measurements of the resting state DMN versus 
task-activated semantic memory processes in predicting future 
cognitive decline among asymptomatic persons. 
Baseline hippocampal volume, corrected for intracranial volume, 
significantly predicted future cognitive decline, both alone and 
combined with APOE genotype. However, its predictive accuracy was 
not as strong as the combination of fMRI and APOE genotype. 
Considerable inter- individual variability in hippocampal volumes 
occurs in cross-sectional studies of cognitively intact elders, and 
hippocampal volume may sometimes be inversely related to cognitive 
abilities [95]. A recent meta-analysis concluded that the relationship 
between hippocampal size and episodic memory performance across 
the lifespan was weak [96]. While rate of hippocampal atrophy has 
provided more compelling evidence of a relationship with cognitive 
decline in  healthy older adults [97-99], the requirement of two 
measurement periods separated by up to two or more years makes 
this biomarker impractical for widespread use for enriching prevention  
trials. 
This study adds to the growing body of literature showing that 
combinations of biomarkers show greater predictive accuracy 
compared to individual biomarkers [16, 100]. A stepwise combination 
of biomarkers might be considered for balancing invasiveness, cost-
containment, and predictive accuracy when used in the context of 
identifying at-risk, but otherwise healthy, participants for prevention 
trials. For instance, a prevention trial screening process might include 
APOE genotyping as a first step, followed by task-related fMRI 
activation performed in APOE ε4 carriers. More invasive tests, such as 
CSF biomarkers and PET imaging (FDG or amyloid), could then be 
administered as further selection criteria for enriching study samples. 
However, because we did not perform these additional tests, we 
cannot state conclusively whether these procedures provide 
incremental predictive accuracy beyond the combination of APOE 
genotyping and task-activated fMRI. 
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It is important to acknowledge other limitations of this study. 
Our neuropsychological battery focused on cognitive abilities most 
likely to be affected in early AD and may have missed significant 
changes in other cognitive domains among our stable participants. Our 
study also defined cognitive decline based on change in 
neuropsychological test scores rather than on a change in diagnostic 
category, i.e., conversion to MCI or early AD. In our opinion, the rate 
of conversion from intact cognition to MCI/AD is too low to be used as 
a meaningful outcome variable in prevention trials. Nevertheless, the 
extent to which increased baseline fMRI   activation is specific to 
predicting early AD-related changes or more general age-related  
cognitive decline will await long-term follow-up studies. Finally, despite 
the fact that all participants performed within normal limits at baseline 
on all cognitive measures, baseline neuropsychological performance 
demonstrated non-significant trends for lower performance in the 
declining group on the two RAVLT measures and on the MMSE. Thus, it 
is conceivable that several participants in the declining group were 
actively undergoing cognitive decline. However, our outcome measure 
was based on the degree of cognitive decline from baseline 
performance (1 SD or more) rather than absolute levels of 
performance. Furthermore, our regression-based approach to defining 
cognitive change controlled each participant’s follow-up level of 
performance for his or her baseline level of performance. Small 
baseline differences would be unlikely to account for the dramatic 
cognitive change in the declining group relative to the stable group as 
depicted in Figure 1. 
In summary, our study provides evidence of the ability of task-
related fMRI, in combination with APOE genotype, to predict future 
cognitive change in healthy older adults. This  combination of static 
genetic propensity to develop AD and an fMRI approach that measures  
brain activity during a low-effort, high accuracy task, can be valuable 
for enriching a prevention trial with healthy persons at high risk of 
impending cognitive decline. Biomarker combinations tapping different 
aspects of pathological changes associated with AD that are widely 
available, easily implemented, minimally invasive, and relatively 
inexpensive will likely assume increasing importance in future clinical 
trials designed to prevent or slow AD  progression. 
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Table 1. Sample characteristics, neuropsychological performance and fMRI 
behavioral data for stable and declining groups. 
 
Note: MMSE=Mini-Mental State Examination; DRS-2=Mattis Dementia Rating Scale-
2; RAVLT=Rey Auditory Verbal Learning Test; DR = delayed recall; IADL=Instrumental 
Activities of Daily Living; GDS=Geriatric Depression Scale; d’=signal detection 
discrimination; RT=Reaction Time.        * = data were constant. 
 
Table 2. Activation foci for famous versus unfamiliar name subtraction (Famous > 
Unfamiliar)* 
Note: Critical value (2*rcrit, p=.01) used to identify significant component loadings 
was 0.560 [80]. *= PCA conducted on four negative activation (Unfamiliar > Familiar) 
clusters (Left Precentral Gyrus; Bilateral Supplementary Motor Area; Right Insula; Left 
Middle Occipital Gyrus) revealed one component that did not predict decline; this 
component was dropped from subsequent analyses. 
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Table 3. Results of logistic regressions 
 
Note: Adequacy index reflects the total explanatory power of a subset of 
predictors relative to a model containing the total set of predictors (Model 7) 
using the ratio of the likelihood ratio of the model of interest to the likelihood 
ratio of the model containing the total set of predictors. 
 
FIGURE LEGENDS 
Figure 1. Mean baseline and follow-up performance (with standard 
errors) on principal neuropsychological outcome measures for cognitively 
stable and declining participants. There were no significant (p < 0.05) group 
differences at baseline. The 18-month follow-up shows expected group 
differences in cognitive functioning, validating the group selection criteria. 
Figure 2. Group differences in activation derived from the 
comparison of the famous versus unfamiliar names condition: Famous > 
Unfamiliar represented in red; Unfamiliar > Famous in blue. Note the greater 
spatial extent of activation in the Famous > Unfamiliar names comparison in 
the stable group. 
Figure 3. A) Regions comprising the Cortical (green) and 
Hippocampal (purple) fMRI activation principal components for the Famous > 
Unfamiliar names comparison. B) Cortical and Hippocampal fMRI signals 
(areas under the curve) contrasting famous name recognition versus fixation 
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and unfamiliar name identification versus fixation for cognitively stable and 
declining participants. 
Figure 4. Odds ratios and 95% confidence intervals for seven logistic 
regression models. Odds ratios whose 95% confidence intervals overlap with 
1.0 (represented by vertical dashed line) are not statistically significant. Odds 
ratios > 1 indicate greater probability of decline with increasing value of 
predictor; odds ratios < 1 indicate reduced probability with increasing 
predictor   values. 
Figure 5. Percent MR signal intensity (± SEM) for stable and 
declining APOE ε4 carriers (ε4+) and non-carriers (ε4-). Positive values reflect 
greater BOLD response aggregated across activated cortical regions in 
response to famous relative to unfamiliar names; negative values reflect 
greater BOLD response to unfamiliar relative to familiar  names. 
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